C-reactive Protein in Patients with Metastatic Clear Cell Renal Carcinoma: An Important Biomarker for Tumor-associated Inflammation

Reichle, Albrecht; Grassinger, Jochen; Bross, K. J.; Wilke, Jochen; Suedhoff, Thomas; Walter, Bernhard; Wieland, W.F.; Berand, Anna; Andreesen, Reinhard

doi:10.1177/117727190600100017

Cited by 12 publications

(29 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But in a subsequent study, IFN-seemed to act complementary tilting the systems biology of the tumor to a measurable response with inflammation control in all patients with initially elevated CRP (C reactive protein) levels [30]. But in a subsequent study, IFN-seemed to act complementary tilting the systems biology of the tumor to a measurable response with inflammation control in all patients with initially elevated CRP (C reactive protein) levels [30].…”

Section: Role Of Ppar / In the Regulation Of Antitu-moral Immunitymentioning

confidence: 94%

Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) Agonists

Bundscherer¹,

Reichle²,

Hafner³

et al. 2009

ACAMC

Self Cite

View full text Add to dashboard Cite

Tumor cells depend on and are able to modulate the tumor stroma establishing a permissive and supportive environment of their own. Targeting the tumor stroma has evolved as a novel concept that has attracted attention of cancer researchers aiming at the treatment of metastatic cancer. The novel paradigm is that modulating the stroma will possibly not cure the cancer, but will make it a manageable disease for long periods of time by prohibiting the cancer from growing beyond a certain mass. Accordingly, in the last years, a multitude of stroma-targeting agents were developed comprising either classic small molecule drugs (e.g. sorafenib, an inhibitor of multiple tyrosine kinases) or recombinant antibodies (e.g. anti-VEGF) for targeting of tumor angiogenesis. Apart from these specifically targeted drugs, some well established drugs, primarily designed for non-oncologic diseases, have revealed antitumor activity on the basis of nuclear receptor modulation unfolding pleiotropic biological effects including stroma modulation. Peroxisome Proliferator Activated Receptor (PPAR) agonists, particularly thiazolidinedione derivatives such as pioglitazone and ciglitazone, are promising examples as they exert both a direct antitumoral and a broad spectrum of anti-stromal, antiangiogenic and immuno-modulating activities. This review will focus on the stroma-mediated anticancer activities of PPAR agonists.

show abstract

Section: Role Of Ppar / In the Regulation Of Antitu-moral Immunitymentioning

confidence: 94%

Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) Agonists

Bundscherer¹,

Reichle²,

Hafner³

et al. 2009

ACAMC

Self Cite

View full text Add to dashboard Cite

show abstract

“…In metastatic RCCC, we selected in a second consecutive trial an anti-inflammatory approach with presumably enhanced anti-inflammatory capacity: pioglitazone, coxib, and additionally interferon-alpha [ 12 ]. In HRPC, a combination of two activators of nuclear transcription factors (pioglitazone and dexamethasone) has been introduced [ 14 ].…”

Section: Methodsmentioning

confidence: 99%

Systems Biology: A Therapeutic Target for Tumor Therapy

Reichle

Vogt

2008

Cancer Microenvironment

Self Cite

View full text Add to dashboard Cite

Tumor-related activities that seem to be operationally induced by the division of function, such as inflammation, neoangiogenesis, Warburg effect, immune response, extracellular matrix remodeling, cell proliferation rate, apoptosis, coagulation effects, present itself from a systems perspective as an enhancement of complexity. We hypothesized, that tumor systems-directed therapies might have the capability to use aggregated action effects, as adjustable sizes to therapeutically modulate the tumor systems' stability, homeostasis, and robustness. We performed a retrospective analysis of recently published data on 224 patients with advanced and heavily pre-treated (10% to 63%) vascular sarcoma, melanoma, renal clear cell, cholangiocellular, carcinoma, hormone-refractory prostate cancer, and multivisceral Langerhans' cell histiocytosis enrolled in nine multi-center phase II trials (11 centers). Each patient received a multi-targeted systems-directed therapy that consisted of metronomic low-dose chemotherapy, a COX-2 inhibitor, combined with one or two transcription modulators, pioglitazone +/− dexamethasone or IFN-alpha. These treatment schedules may attenuate the metastatic potential, tumor-associated inflammation, may exert site-specific activities, and induce long-term disease stabilization followed by prolonged objective response (3% to 48%) despite poor monoactivity of the respective drugs.Progression-free survival data are comparable with those of reductionist-designed standard first-line therapies. The differential response patterns indicate the therapies' systems biological activity. Understanding systems biology as adjustable size may break through the barrier of complex tumor-stroma-interactions in a therapeutically relevant way: Comparatively high efficacy at moderate toxicity. Structured systems-directed therapies in metastatic cancer may get a source for detecting the topology of tumor-associated complex aggregated action effects as adjustable sizes available for targeted biomodulatory therapies.

show abstract

“…Pathological reactions caused by a stress response to surgical operations, such as immunosuppression and metabolic disturbances, are related to tumour necrosis, nutritional status and prognosis to some degree (15,16). It has been widely shown that changes in serum CRP, IL-6 and T lymphocyte counts in peripheral blood are indices of immune response after tumour operation (17,18).…”

Section: Discussionmentioning

confidence: 99%

Safety and effectiveness of percutaneous radiofrequency ablation in early stage renal cell carcinoma

Liu

Gao

2016

Oncology Letters

View full text Add to dashboard Cite

The purpose of this study was to analyze the safety and effectiveness of percutaneous radiofrequency ablation (RFA) in early stage renal cell carcinoma. A total of 76 patients suffering from early stage renal cell carcinoma were selected and randomly assigned into the observation group (41 cases) or the control group (35 cases). Percutaneous RFA was used in the observation group, while retroperitoneoscopic radical operation of renal cell carcinoma was used in the control group, and the operative effects were compared. In the observation group, operation time, blood loss during operation, length of stay and incidence rate of complications were lower than those in control group (P<0.05). For both groups, serum C-reactive protein, interleukin-6 and T lymphocyte counts at 1, 2 and 3 days after operation were all increased; however, the control group had significantly greater increase for all the time points (P<0.05). For total effective rates, tumour-free survival times and survival rates, there were no statistically significant differences between the two groups (P>0.05). Percutaneous RFA has a reduced size of operation wound and a quick postoperative recovery time in the treatment of early stage renal cell carcinoma. It results in less inflammation and immunity-based injuries in the body and achieves the same clinical outcomes as retroperitoneoscopic radical operation of renal cell carcinoma.

show abstract

C-reactive Protein in Patients with Metastatic Clear Cell Renal Carcinoma: An Important Biomarker for Tumor-associated Inflammation

Cited by 12 publications

References 51 publications

Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) Agonists

Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) Agonists

Systems Biology: A Therapeutic Target for Tumor Therapy

Safety and effectiveness of percutaneous radiofrequency ablation in early stage renal cell carcinoma

Contact Info

Product

Resources

About